Plné znění - 80/2017 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2017 - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

80/2017 Sb. m. s.

Sdělení

INFORMACE

80

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx věcí,

kterým xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Xx. m. x. x x. 46/2008 Xx. m. x.

 

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 28. xxxxxxxxx 2016 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx znění Přílohy X (Xxxxxx zakázaných xxxxx a xxxxx xxxxxxx xxx rok 2017 - Xxxxxxxxxxx xxxxxxxx) Xxxxxxxxxxx úmluvy xxxxx dopingu xx xxxxxx¹⁾.

X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x přijetí xxxx Xxxxxxx X Českou xxxxxxxxxx.

Xxxx znění Přílohy X xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2017 x pro Xxxxxx xxxxxxxxx vstoupilo x xxxxxxxx xxx 30. xxxxx 2017.

Xxxx xxxxxx xxxxxx xxxxx Přílohy X x xxxxxxxx xxxxxxxx platit xxxxx Xxxxxxx I xxxxxx xx 1. xxxxx 2016, xxxxxxxxx xxx č. 26/2017 Sb. m. s.

Xxxxxxxx znění Xxxxxxx X x xxxx xxxxxxx xx českého xxxxxx se xxxxxxxxx xxxxxxxx.

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX XXXXX X XXXXX DOPINGU XXX XXX 2017

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx bude xxxxxxxxx XXXX x xxxx xxxxxxxxxx x xxxxxxxxxx a xxxxxxxxxxxxx.

X xxxxxxx jakýchkoliv konfliktů xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxx bude xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Xxxxxx xxxx xxxxxx xx 1. xxxxx 2017 

XXXXXX ZAKÁZANÝCH XXXXX X XXXXX XXXXXXX XXX ROK 2017

XXXXXXX XXXXXXXXXXXXX XXXXX

Xxxxxx xx 1. xxxxx 2017

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx budou xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx S1, X2, X4.4, X4.5 x X6(x) x Xxxxxxxxxx metod M1, X2 x X3.

XXXXX X METODY XXXXXXXX XXXXX (XXX XXXXXXX A XXXX XXXXXX)

XXXXXXXX XXXXX

X0. XXXXXXXXXXX LÁTKY

Jakákoliv farmakologicky xxxxxx látka, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx xxxxxxxx xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx jakýmkoliv xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (např. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx schválené pouze xxx veterinární použití), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

1. ANABOLICKÉ XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* XXX, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

xxxxxxxxx (estr-4-en-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17ß-ol);

gestrinon;

4-hydroxytestosteron (4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx);

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-hydroxy-2α,17α-dimethyl-5α-androstan-3-on);

methyldienolon (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými biologickými xxxxxx.

x. Endogenní** XXX, xxxxx xxxx podány xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxxxx-3xx); 

xxxxxxxxx (19-xxxxxxxxxxxxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x jejich xxxxxxxxxx x xxxxxxx, xxx xx x xxxxxxxx pouze na xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (SARM, xxxx. xxxxxxx x xxxxxxx); xxxxxxx; xxxxxxx x zilpaterol, ale xx x omezením xxxxx xx xx.

Xxx xxxxx skupiny této xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, xxxxxx xxxx normálně xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " se vztahuje x xxxxx, xxxxxx xxxx normálně xxxxxxxxx xxxxxxxxx.

X2. PEPTIDOVÉ XXXXXXX, XXXXXXX FAKTORY, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx xxxxx a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx:

1. Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx:

1.1 Xxxxx xxxxxxxxxxx xxxxxxxxxxx (XXX) xxxxxx xxxx.

xxxxxxxxxxxx (xXXX);

xxxxxxxxxxxxx (XXX);

XXX-Xx;

XXX-xxxxxxxxxxx xxxxxxx (XXX), xxxx. XXXX 530 x xxxxxxxxxxx;

xxxxxxxxxx XXXX, xxxx. X-11706;

xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX);

xxxxxxxxxx transformujícího xxxxxxxxx xxxxxxx xxxx (XXX-xxxx), xxxx. xxxxxxxxxxx, luspatercept;

1.2 Xxxxxxxx xxxxxxxxxxxxxxxxxx EPO xxxxxxxxx, např.

ARA-290;

asialo EPO;

karbamylovaný XXX;

2. Xxxxxxxxxxxxx hypoxii xxxxxxxxxxxxxx faktoru (HIF), xxxx. kobalt, xxxxxxxxxx x roxadustat (XX-4592); x aktivátory XXX, xxxx. xxxxx x xxxxx.

3. Xxxxxxxxxxxxxxxxxx (CG) x xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx xxxxxxx, např. xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx, x mužů.

4. Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx.

5. Xxxxxxx xxxxxx (XX) a xxxx xxxxxxxxxx xxxxxxx xxxxxx: xxxxxxx xxxxxxxxxxxx růstový xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1295, xxxxxxxxxxx x xxxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), např. xxxxxxxx x xxxxxxx xxxxxxxx, např. xxxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxxx xxxxxxx růstového hormonu (XXXX), např. xxxxxxxxxxxxx, XXXX-6, xxxxxxxxxx x xxxxxxxxxxxx (XXXX- 2).

Xxxxx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx:

Xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx); xxxxxxxxxxxx růstový xxxxxx (XXX); xxxxxxxx podobný xxxxxxx faktor-1 (XXX-1) x jeho xxxxxxx; xxxxxxxxxx xxxxxxx faktory (XXX); xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (PDGF); xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), xxxxxx jako jakékoliv xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx nebo xxxxxxxxx xxxxxxxx svalů, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxxxxxxxx i xxxxxxxxxxxx beta2- agonisté, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx x xxxxxxxx pouze xx xx):

Xxxxxxxxx; xxxxxxxxxx; higenamin; xxxxxxxxxxx; xxxxxxxxxx; prokaterol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx za 24 xxxxx, xxxxxxxxxxx 800 xxxxxxxxxx za xxxxxxx 12 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 hodin;
• inhalační xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin.

Přítomnost xxxxxxxxxxx v xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x přítomnost formoterolu x moči x xxxxxxxxxxx vyšší xxx 40 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx xx xxxxxxxxx laboratorní nález, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx užíváním xxxxxxxxxxxx dávky (v xxxxxxxx) xxxxx, než xxxx xxxxxxx maximální xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:

1. Inhibitory xxxxxxxx, zahrnující:

Aminoglutethimid;

anastrozol;

androsta-1,4,6-trien-3-17-dion (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx,

xxx xx x xxxxxxxx xxxxx xx xx.

2. Selektivní xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

tamoxifen;

toremifen, xxx xx x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:

Xxxxxxxxxx; fulvestrant x klomifen, ale xx s omezením xxxxx xx xx.

4. Xxxxx modifikující funkci(e) xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, ale xx

x xxxxxxxx xxxxx xx xx.

5. Xxxxxxxxxxx xxxxxxxxxx:

5.1 Xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. AICAR; x Xxxxxxxx Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (PPARδ), např. XX 1516;

5.2 Xxxxxxxx x mimetika xxxxxxxx;

5.3 Xxxxxxxxx;

5.4 Trimetazidin.

S5. XXXXXXXXX X XXXXXXXXX LÁTKY

Následující xxxxxxxxx a xxxxxxxxx xxxxx jsou xxxxxxxx, xxxxxx jako xxxxx xxxxx s podobnou xxxxxxxxx xxxxxxxxxx a xxxxxxxxx xxxxxxxxxxxx účinky.

Zahrnují:

• Desmopressin, xxxxxxxxxxxxxxx (xxxx. glycerol, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, hydroxyethylškrobu x xxxxxxxxx), xxxxxxxxxx, ale xx s xxxxxxxx xxxxx na xx.

• Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, indapamid, xxxxxxxx, xxxxxxxx xxxxxxxxxx, metolazon, xxxxxxxxxxxxx, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x vaptany (xxxx. tolvaptan), xxx xx x xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx, xxxxxxxxx x xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx (např. xxxxxxxxxxx x brinzolamidu)

• Lokálního xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx stanoveným xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, katin, xxxxxxx, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo

případně Xxx Xxxxxxx ve xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, bude xxxxxxxxxx xx Xxxxxxxxx laboratorní xxxxx, xxxxx Sportovec xxxx xxxxxxxxxx Terapeutickou xxxxxxx (TV) xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx udělena xx diuretikum xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX S XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je následující:

1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx nebo xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.

2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx produkty (např. xxxxxx náhražky xxxxxxxx xx hemoglobinu x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx ne x xxxxxxxx xxxxx xx xx. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx není.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx způsoby.

M2. XXXXXXXX X XXXXXXXXX MANIPULACE

Zakázané xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, za účelem xxxxxxx xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx úpravu (xxxx. xxxxxxxxxx) xxxx, xxx xx s xxxxxxxx xxxxx xx ně.

2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxx 50 xx za 6 hodin xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx, xxxxxxxxxxxxx zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx zakázáno xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx modifikovaných xxxxx;

XXXXX X XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx xxxxxxxxx X0 až X5 x X1 xx X3 xxxxxxxxx xxxx

xxxx Při Xxxxxxx xxxxxxxx i xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx optických xxxxxxx, xxxx. d- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/,

xxxxxxxxxx,

xxxxxxxxxxx,

xxxxxx,

xxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx (x-),

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxxxx, 

x-xxxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, je Xxxxxxxxxxx látkou.

(b) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (ale xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx (epinefrin)****,

benzfetamin,

dimethylamfetamin,

efedrin***,

etamivan,

etylamfetamin,

etylefrin,

famprofazon,

fenbutrazát,

fenetylamin x xxxx xxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxx,

xxxxx**,

xxxxxxx x xxxx xxxxxxx (např. xxxxxxxx, xxxxxxxxx a xxxx-xxxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxxxx***,

xxxxxxxxxxxxxxxxxxxxxxxx,

xxxxxxxxxxxx,

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx),

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxx (xxxxxxxxxxxxx),

xxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxxxx,

xxxxxxxxxxxxx*****,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx),

xxxxxxxxxxxxx

x xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x xxxxxxx jejich xxxxxxxx/xxxxxx xxxxxxx a xxxxxxxxxxx xxxxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx pro xxx 2017*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol x xxxxxxxx: Tyto látky xxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2017 x xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.

** Xxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx moči.

*** Xxxxxxx x methylefedrin: xxxx xxxxxxxx xxx koncentraci xxxxx než 10 xxxxxxxxxx x 1 xx xxxx.

**** Adrenalin (xxxxxxxxx): xxxx xxxxxxx xxx lokálním podání, xxxx. xxxxx, xxxx xxxxxxxx xxxx jeho xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

Xxxxxxxxxxx,

xxxxxxxxxxxxx,

xxxxxxxxx(xxxxxx),

xxxxxxxx x xxxx deriváty,

hydromorfon,

metadon,

morfin,

nikomorfin,

oxykodon,

oxymorfon,

pentazocin,

petidin.

S8. XXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

• Xxxxxxxx (xxxx. xxxxx, xxxxxx x xxxxxxxxx) nebo syntetický xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX).

• Xxxxxxxxxxxxxx, xxxx. "Xxxxx", XXX018, JWH073 x HU-210.

S9. XXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

XXXXX XXXXXXXX V URČITÝCH XXXXXXXX

X1. XXXXXXX

Xxxxxxx (etanol) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Detekce xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx porušení xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx koncentraci xxxxxxxx x xxxx 0,10 x/x.

• Xxxxxxxxxxxx xxxxx (FIA)

• Lukostřelba (XX)

• Xxxxxxx xxxxxx x xxxxxxxxxxxx (XXX)

• Xxxxx motorismus (XXX)

X2. BETA-BLOKÁTORY

Beta-blokátory xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx, x xxx xx to xxxxxxxx x Mimo xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (všechny xxxxxxxxxx) (XXXX)

• Xxxx (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x xxxxxxxxx X-xxxxx a "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (XXXX) x xxxxxxxxxxxx konstantní xxxx x xxxxxxxxx xxxx bez ploutví, xxxxxxxxx apnoe x xxxxxxxxx xxxx xxx xxxxxxx, xxxx xxxxxxxxx, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx apnoe, střelba xxxxxxxx na xxxx x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (WDF)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxxx,

xxxxxxx,

xxxxxxxxx,

xxxxxxxxxx,

xxxxxxxxx,

xxxxxxxxxxx,

xxxxxxxxxxxx,

xxxxxxxxxx, 

xxxxxxx,

xxxxxxxxxx,

xxxxxxxx,

xxxxxxxxxxx,

xxxxxxx,

xxxxxxx,

xxx ne s xxxxxxxx xxxxx xx xx.

Informace

Právní xxxxxxx č. 80/2017 Sb. m. x. nabyl účinnosti xxxx 4.1.2018.

Xxxxxx předpis x. 80/2017 Xx. x. s. xxx xxxxxx xxxxxxx xxxxxxxxx č. 36/2019 Sb. m. s. s xxxxxxxxx xx 26.7.2019.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů v xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx, xxxxxxx dne 19. xxxxx 2005 x Xxxxxx, xxxx xxxxxxxxx x xxxxxxxxx xxxxx x x xxxxxxxxx xx xxxxxxx xxxxxx pod č. 58/2007 Sb. m. s.

Xxxx xxxxx xxxxxxxx Xxxxxx xx xxxxxxx xxxxxx xxxx xxxxxxxxx pod č. 46/2008 Sb. m. s.